Jemperli (dostarlimab)

pCPA File Number: 21991
Negotiation Status:
Negotiations were not pursued
Indication(s):
Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum containing regimen, in adult patients
Sponsor/Manufacturer:
GlaxoSmithKline Inc.
CDA-AMC Project Number:
PC0263-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded: